Cat. No.
MABL-875
Application
inhibit, ELISA, FC, IF, IHC
Isotype
Engineer antibody
Species Reactivity
Human
Clone No.
Ki-4
From
Recombinant Antibody
Specificity
The antibody binds to CD30.
Alternative Names
TNFRSF8; Tumor necrosis factor receptor superfamily member 8; CD30L receptor; Ki-1 antigen; Lymphocyte activation antigen CD30
UniProt
P28908
Immunogen
Human CD30.
Application Notes
The antibody binds specifically to CD30, a cell membrane protein which belongs to the tumour necrosis factor receptor family. Incubation of CD30 positive L540 cells with Ki-4 antibody completely inhibits release of soluble CD30 (in contrast to Ki-3, Ab00474). CD30 is expressed on activated lymphocytes, and binding by its ligands TRAF2 and TRAF5 results in the activation of NF-kappaB, thereby regulating gene expression. CD30 is also associated with Hodgkin Lymphoma, and its expression acts as a tumour marker. Targeting the CD30 antigen with specific monoclonal antibodies is a possible therapy for Hodgkin's lymphoma.
Antibody First Published
Horn-Lohrens O, Tiemann M, Lange H, Kobarg J, Hafner M, Hansen H, Sterry W, Parwaresch RM, Lemke H. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4). Int J Cancer. 1995 Feb 8;60(4)：539-44.PMID：7530238
Note on publication
Describes the role of CD30 in the detection of Hodgkin lymphoma, and the production of monoclonal antibodies to inhibit the formation of soluble CD30 and thereby allow the production of immunotoxins.
Size
100 μg Purified antibody.
Concentration
1 mg/ml.
Purification
Protein A affinity purified
Buffer
PBS with 0.02% Proclin 300.
Storage Recommendation
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.
